Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aurore Perrot

Showing results (1-10 of 185) with videos related to

Pageof 19
Sort By:
Blood|November 17, 2021
How I treat frontline transplantation-eligible multiple myelomaAurore Perrot
Hematology. American Society of Hematology. Education Program|December 7, 2024
Transplant in myeloma: who, when, and why?Aurore Perrot
Presse Medicale (Paris, France : 1983)|December 11, 2024
Evolving strategies in the management of transplant-eligible patients with newly diagnosed multiple myelomaAurore Perrot
Blood|January 17, 2025
Daratumumab for maintenance in myelomaCyrille Touzeau, Aurore Perrot
The Lancet. Haematology|March 14, 2026
Maintenance intensification after allogeneic HSCT: refining selectionAurore Perrot, Laurent Frenzel
La Revue Du Praticien|July 28, 2022
[Nouveaux traitements du myélome multiple]Anaïs Schavgoulidze, Aurore Perrot
Blood|April 17, 2025
The decline of transplant for relapsed myelomaAurore Perrot, Cyrille Touzeau
La Revue Du Praticien|April 2, 2011
[Superficial adenopathy]Pierre Feugier, Aurore Perrot
Blood|August 7, 2025
Sustained MRD negativity: robust, not all-powerfulAurore Perrot, Jill Corre
Cancer|August 26, 2025
Understanding quality of life under talquetamab: Learning to measure what mattersLisa Leypoldt, Meral Beksac, Aurore Perrot
Pageof 19

Showing results (1-10 of 185) with videos related to

Sort By:
Pageof 19
Blood|November 17, 2021
How I treat frontline transplantation-eligible multiple myelomaAurore Perrot
Hematology. American Society of Hematology. Education Program|December 7, 2024
Transplant in myeloma: who, when, and why?Aurore Perrot
Presse Medicale (Paris, France : 1983)|December 11, 2024
Evolving strategies in the management of transplant-eligible patients with newly diagnosed multiple myelomaAurore Perrot
Blood|January 17, 2025
Daratumumab for maintenance in myelomaCyrille Touzeau, Aurore Perrot
The Lancet. Haematology|March 14, 2026
Maintenance intensification after allogeneic HSCT: refining selectionAurore Perrot, Laurent Frenzel
La Revue Du Praticien|July 28, 2022
[Nouveaux traitements du myélome multiple]Anaïs Schavgoulidze, Aurore Perrot
Blood|April 17, 2025
The decline of transplant for relapsed myelomaAurore Perrot, Cyrille Touzeau
La Revue Du Praticien|April 2, 2011
[Superficial adenopathy]Pierre Feugier, Aurore Perrot
Blood|August 7, 2025
Sustained MRD negativity: robust, not all-powerfulAurore Perrot, Jill Corre
Cancer|August 26, 2025
Understanding quality of life under talquetamab: Learning to measure what mattersLisa Leypoldt, Meral Beksac, Aurore Perrot
Pageof 19